Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

New UK data shows RSV vaccines in pregnant women cut infant hospitalizations by 72%, while premature babies are now protected ...

An RSV vaccine has been available to pregnant women in Northern Ireland since last September and is offered from 28 weeks of ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

The Meissa RSV vaccine candidate Although the data for RSVpreF are promising, it is not meant to be administered to children and infants. A vaccine candidate from Meissa being tested in a phase 1 ...

According to the responses, as of Nov. 9, cumulative estimated vaccine coverage of adults aged 18 years and older for the COVID-19 vaccines was 17.9% and for influenza vaccines was 34.7%. RSV ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond pulmonology, including poor kidney outcomes and cardiovascular conditions, ...